COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu
Trial record 1 of 1 for:    APX005M-010
Previous Study | Return to List | Next Study

A Study to Evaluate APX005M in Subjects With Unresectable or Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04337931
Recruitment Status : Recruiting
First Posted : April 8, 2020
Last Update Posted : April 8, 2020
Information provided by (Responsible Party):
Apexigen, Inc.

Brief Summary:
This is a multicenter, open label, Phase 2 study, with 2 parallel cohorts. The aim of the study is to evaluate the efficacy of APX005M administered at 2 different schedules to adult subjects with unresectable or metastatic melanoma. Enrolled subjects will be alternately assigned to one of 2 cohorts as long as both cohorts are open.

Condition or disease Intervention/treatment Phase
Unresectable Melanoma Metastatic Melanoma Drug: APX005M Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Multicenter, Open-label Study in Two Parallel-Groups to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M in Adults With Unresectable or Metastatic Melanoma
Actual Study Start Date : December 16, 2019
Estimated Primary Completion Date : August 12, 2022
Estimated Study Completion Date : November 12, 2022

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Intervention Details:
  • Drug: APX005M
    2 different administration schedules per treatment cycle
    Other Name: Infusion

Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: 12 months ]
    CR + PR (RECIST 1.1)

Secondary Outcome Measures :
  1. Incidence and severity of AEs and specific laboratory abnormalities [ Time Frame: 12 months ]
  2. ORR by iRECIST [ Time Frame: 12 months ]
  3. Duration of Response [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed unresectable or metastatic melanom
  • Measurable disease by RECIST 1.1
  • Subjects with BRAF activating mutation must have received a BRAF inhibitor and/or MEK inhibitor regimen prior to study entry


  • Use of systemic corticosteroids or other systemic immunosuppressive drugs within the 28 days prior to first dose of investigational product (except inhaled corticosteroids) History of allogeneic bone marrow transplantation
  • Active, known or suspected autoimmune disease
  • Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs)
  • History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis
  • History of interstitial lung disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04337931

Layout table for location information
Jacek Mackiewicz Recruiting
Poznan, Poland
Contact: Jacek Mackiewicz    606 228 277   
Piotr Rutkowski Recruiting
Warsaw, Poland
Contact: Piotr Rutkowski    48 22 546 21 03   
H. San Juan de Alicante Recruiting
Alicante, Spain
Contact: Asunción Juárez    656946004   
H. Quirón Dexeus Recruiting
Barcelona, Spain
Contact: María González Cao    9354 0135   
H. Vall d'Hebron Recruiting
Barcelona, Spain
Contact: Eva Muñoz    +34 274 60 00 ext 4350   
H. Insular de Gran Canaria Recruiting
Gran Canaria, Spain
Contact: Delvys Rodríguez    661 672 235   
H. Doce de Octubre Recruiting
Madrid, Spain
Contact: Jose Antonio Lopez    91 390 89 24   
H. HM Sanchinnarro Recruiting
Madrid, Spain
Contact: Valentina Boni    666 209 969   
H. Virgen de la Arrixaca Recruiting
Murcia, Spain
Contact: Pablo Cerezuela    666496774   
H. U. de Canarias Recruiting
Tenerife, Spain
Contact: Juana Oramas    922 678 204   
Hospital Gral. de Valencia Recruiting
Valencia, Spain
Contact: Alfonso Berrocal    649 967 049   
Sponsors and Collaborators
Apexigen, Inc.
Layout table for additonal information
Responsible Party: Apexigen, Inc. Identifier: NCT04337931    
Other Study ID Numbers: APX005M-010
First Posted: April 8, 2020    Key Record Dates
Last Update Posted: April 8, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas